Cartesian stockholders elect directors, approve incentive plan, ratify auditor at annual meeting

Cartesian Therapeutics, Inc.

Carrie S. Cox (11.8M for) and Murat Kalayoglu (12.1M for) elected to Class II board until 2027.
Stockholders approved amended & restated 2016 Incentive Award Plan (11.3M for, 857K against).
Non-binding advisory vote on executive compensation passed (11.7M for, 444K against).
Ernst & Young ratified as independent auditor for 2024 (13.5M for, 212K against).
Annual meeting turnout: 13.8M shares voted, ~77.3% of outstanding common stock.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.